Alpha-9 Oncology Doses First Patient in Phase 1 Clinical Trial Evaluating GRPR-Targeted Radiotherapeutics Across Multiple Solid Tumors

Phase 1 study evaluates distinct 225Ac and 177Lu compounds in breast cancer and other solid tumors; data expected in late 2027 225Ac-A9-0642 is the first actinium-based GRPR-targeting compound to enter clinical evaluation with the potential to deliver enhanced efficacy compared to first-generation 177Lu approaches 177Lu-A9-0631 is a lutetium-based GRPR-targeting compound with best-in-class potential Alpha-9 takes […] The post Alpha-9 Oncology Doses First Patient in Phase 1 Clinical Trial Evaluating GRPR-Targeted Radiotherapeutics Across Multiple Solid Tumors appeared first on Alpha-9 Oncology